Skip to main content
PASG logo

Passage Bio, Inc.

PASGNASDAQHealthcareBiotechnology

$3.50Today:- (-)1Y −55.39%

As of Oct 16, 2026 close

Market cap
$11.55M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$3.29$20.00
Volume (live)
-
Avg. volume (3M)
26.98K

Passage Bio (PASG) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), Passage Bio used $31.51M of cash in operating activities. Free cash flow was −$31.51M.

Passage Bio Cash Flow Statement Analysis

Values in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Passage Bio, Inc. (PASG) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Operating Activities
Net Income-45.52-64.77-102.06-136.13-185.39-112.23-45.63-12.77
Depreciation & Amortization0.863.083.723.681.540.800.130.00
Deferred Income Tax0.000.000.000.002.780.630.000.00
Stock Based Compensation3.005.8210.9218.9532.6914.581.450.00
Change in Working Capital4.00-4.025.34-8.4911.4214.44-5.94-8.52
Change in Accounts Receivable0.000.000.000.000.000.000.400.21
Change in Accounts Payable1.88-0.56-2.79-5.412.204.590.400.21
Change in Other Working Capital2.129.727.473.0010.089.85-6.74-8.95
Other Operating Activities6.163.713.823.0010.081.2610.092.73
Net Cash from Operating Activities-31.51-47.96-78.26-118.21-126.88-80.52-39.90-18.57
Investing Activities
Capital Expenditures0.00-0.03-0.15-5.27-25.64-1.65-1.69-2.54
Acquisitions1.170.000.000.008.000.500.000.00
Purchases of Investments0.00-88.17-129.43-157.84-202.55-266.060.000.00
Sales/Maturities of Investments39.05143.15194.82188.31182.3795.600.000.00
Other Investing Activities0.000.000.000.00-8.00-0.50-0.500.00
Net Cash from Investing Activities40.2254.9565.2425.20-45.81-172.11-1.69-2.54
Financing Activities
Common Stock Issued0.028.870.140.43165.81228.470.0045.97
Other Financing Activities0.000.130.00-1.79-0.340.28175.6045.97
Net Cash from Financing Activities0.028.870.14-1.35166.66228.75175.6045.97
Summary
Net Change in Cash8.7315.86-12.89-94.36-6.04-23.87134.0124.86
Cash at Beginning of Period37.5721.7134.60128.97135.00158.8724.860.00
Cash at End of Period46.3037.5721.7134.60128.97135.00158.8724.86
Free Cash Flow-31.51-47.99-78.41-123.48-152.52-82.17-41.59-21.11

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Passage Bio Cash Flow

What is Passage Bio's free cash flow?

Passage Bio had negative free cash flow of $31.51M in fiscal 2025 (fiscal year ended Dec 31, 2025).

Does Passage Bio pay dividends or buy back shares?

Passage Bio's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition